Menu Search
Equities

HitGen Inc

688222:SHH

HitGen Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)8.56
  • Today's Change-0.09 / -1.04%
  • Shares traded3.39m
  • 1 Year change-42.20%
  • Beta1.0448
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The one analyst offering a 12 month price target expects HitGen Inc share price to rise to 11.80 in the next year from the last price of 8.50.
High38.8%11.80
Med38.8%11.80
Low38.8%11.80

Dividends

In 2023, HitGen Inc reported a dividend of 0.05 CNY. The analyst covering the company expects dividends of 0.02 CNY for the upcoming fiscal year, a decrease of 60.00%.
Div growth (TTM)--
More ▼

Earnings history & estimates in CNY

On Oct 28, 2022, earnings of 0.04 per share.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate-54.05%
HitGen Inc reported annual 2023 earnings of 0.10 per share on Feb 23, 2024.
Average growth rate-3.06%
More ▼

Revenue history & estimates in CNY

of 111.49m. This missed the 111.49m estimate of the one analyst following the company.
Average growth rate+9.56%
HitGen Inc had revenues for the full year 2023 of 371.33m. This was 12.64% above the prior year's results.
Average growth rate+15.44%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.